SK Bioscience to Build mRNA Vaccine Factory

SK Bioscience will build a W150 billion mRNA vaccine production facility (US$1=W1,134).

The company said Monday that the plant will be part of its manufacturing complex in Andong, North Gyeongsang Province.

It will invest W150 billion by 2024 to set up the new production lines so it can become a major regional vaccine hub.

The company is already producing the AstraZeneca coronavirus vaccine, which is not mRNA-based, and signed a deal in August last year to produce the Novavax vaccine as well.